Catalina Vasquez
About
Catalina Vasquez is from Canada. Catalina works in the following industries: "Biotechnology Research". Catalina is currently Business Development Lead at Prime Diagnostics, located in Colombia. Catalina also works as Clinical Development SARS-CoV-2 Vaccine at Entos Pharmaceuticals, a job Catalina has held since May 2020. Another title Catalina currently holds is Co-Founder & COO at Nanostics Inc. In Catalina's previous role as a Director/Manager, Alberta Prostate Cancer Research Initiative at Alberta Prostate Cancer Research Initiative , Catalina worked in University of Alberta until May 2021. Prior to joining Alberta Prostate Cancer Research Initiative , Catalina was a Clinical Trial Project Management Coordintor at London Health Sciences Centre and held the position of Clinical Trial Project Management Coordintor at London, Canada Area. Prior to that, Catalina was a Lawson Translational Cancer Research Team (LTCRT) Coordinator at London Health Sciences Centre, based in London Regional Cancer Program from Apr 2012 to Jul 2013. Catalina started working as Research Laboratory Manager at Western University in London Regional Cancer Program in Sep 2011. From Dec 2003 to May 2007, Catalina was Medical Laboratory Analyst, Laboratory and Quality Team Coordinator at Hospital Santa Isabel, based in San Pedro de los Milagros, Antioquia, Colombia. Prior to that, Catalina was a Medical Laboratory Analyst and Laboratory Coordinator at Hospital San Juan de Dios, based in Antioquia, Colombia from Jun 2002 to Feb 2003.
If you’re looking for Catalina Vasquez's email address, you can find it on finalscout.com. Finalscout is a professional database with more than 500 million business professionals and 200 million company profiles.
Catalina Vasquez's current jobs
Nanostics is an Alberta-based company focused on the development and commercialization of novel, non-invasive diagnostic tests for cancer and other diseases. Our core technology is an advanced liquid biopsy platform and state of the art machine learning for accurate diagnoses from a single drop of blood. The technology is applicable to a wide range of diseases including prostate, ovarian, pancreatic cancers, as well as cardiovascular, degenerative and neurological diseases and to predict risk of transplant rejection. Nanostics’ lead product, ClarityDx, is the most accurate diagnostic test to diagnose aggressive prostate cancer, and is positioned to emerge as the world’s leading diagnostic tool for prostate cancer. Our goal is to reduce the burden of Cancer by improving the accuracy and timeliness of Cancer diagnosis.
Catalina Vasquez's past jobs
Jul 2013-Jan 2018 / Apr 2020-May 2021. The Alberta Prostate Cancer Research Initiative (APCaRI) brings together of more than 200 prostate cancer scientists, physicians, trainees and healthcare employees from five leading Alberta health research institutions are working with an international collaborative network to facilitate successful clinical translation of new technologies to the clinic. Our ultimate goal is to make a meaningful impact on health policy and the outcomes of patients living with prostate cancer.